Impact of Omicron variant infection on the liver, kidney, and coagulation system in patients undergoing elective surgery: a retrospective case-control study.

"Competing Interests: The authors have declared that no competing interest exists."

"Among 5732 patients who underwent elective surgery between October 2022 and January 2023, 5029 patients were enrolled. Based on their surgical data, the enrolled patients were divided into two groups: Group 1 (the control group) consisted of patients who underwent elective surgery between October 2022 and November 2022 and were not infected with the Omicron variant; Group 2 (the experimental group) included patients who underwent elective surgery between December 2022 and January 2023, one month after they contracted the Omicron variant. We further divided the patients into two subgroups for analysis: the tumor subgroup and the nontumor subgroup. Pre- and postoperative values of various indicators, including coagulation parameters, liver function, CBC, and kidney function, were collected and compared to determine the differences between the two groups. When the sample data loss exceeded 20%, the data were promptly discarded. When the sample size was less than 20%, SPSS software was used to impute the missing data. Given that this was a retrospective study, the Ethics Committee waived the requirement for obtaining informed consent forms from the patients. This study was approved by the Army Medical Center of PLA (ratification number is 2023 177) on May 4, 2023. The study was registered with the WHO International Clinical Trial Registration (ChiCTR2300071913)."